GlassScriptPhysician profile
Michael Butler
NPI 1306058557
$108,595.90
in general payments reported to CMS, 2019-2025
39 companies · $9,697 in 2025
The $9,697 reported for 2025 was more than what 88% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,033 · 2020: $9,298 · 2021: $9,022 · 2022: $18K · 2023: $21K · 2024: $34K · 2025: $9,697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $41K · Food and Beverage: $8,782 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,875 · Travel and Lodging: $6,876.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $41,112.50 |
| Food and Beverage | $8,781.82 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,875.00 |
| Travel and Lodging | $6,875.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $87,468.75 | 2019-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve, Evoque |
| Amgen INC. | $8,064.87 | 2019-2025 | Repatha, Repatha |
| Abbott Laboratories | $3,841.02 | 2019-2025 | Triclip, Navitor, Mitraclip |
| Novartis Pharmaceuticals Corporation | $1,737.75 | 2019-2025 | |
| Boston Scientific Corporation | $1,393.39 | 2019-2025 | Avvigo Guidance System, Watchman Flx, Watchman Access System |
| Pfizer INC. | $810.34 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $774.83 | 2019-2024 | Xarelto |
| Medtronic, INC. | $563.07 | 2021-2025 | Corevalve Evolut R, Onyx Frontier, Hawkone |
| Boehringer Ingelheim Pharmaceuticals, INC. | $545.29 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $510.94 | 2019-2025 | Camzyos, Eliquis |
| Abiomed | $397.28 | 2022-2025 | Impella |
| Regeneron Healthcare Solutions, INC. | $307.83 | 2019-2025 | Evkeeza, Praluent |
| Bayer Healthcare Pharmaceuticals INC. | $237.64 | 2020-2025 | |
| Sanofi-Aventis U.S. LLC | $215.78 | 2019-2024 | |
| Esperion Therapeutics, INC. | $204.09 | 2020-2023 | Nexletol |
Show all 37 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Butler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.